216 related articles for article (PubMed ID: 22042371)
1. Breast tenderness and breast cancer risk in the estrogen plus progestin and estrogen-alone women's health initiative clinical trials.
Crandall CJ; Aragaki AK; Cauley JA; McTiernan A; Manson JE; Anderson G; Chlebowski RT
Breast Cancer Res Treat; 2012 Feb; 132(1):275-85. PubMed ID: 22042371
[TBL] [Abstract][Full Text] [Related]
2. Breast tenderness after initiation of conjugated equine estrogens and mammographic density change.
Crandall CJ; Aragaki AK; Cauley JA; McTiernan A; Manson JE; Anderson GL; Wactawski-Wende J; Chlebowski RT
Breast Cancer Res Treat; 2012 Feb; 131(3):969-79. PubMed ID: 21979747
[TBL] [Abstract][Full Text] [Related]
3. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study.
Shumaker SA; Legault C; Kuller L; Rapp SR; Thal L; Lane DS; Fillit H; Stefanick ML; Hendrix SL; Lewis CE; Masaki K; Coker LH;
JAMA; 2004 Jun; 291(24):2947-58. PubMed ID: 15213206
[TBL] [Abstract][Full Text] [Related]
4. New-onset breast tenderness after initiation of estrogen plus progestin therapy and breast cancer risk.
Crandall CJ; Aragaki AK; Chlebowski RT; McTiernan A; Anderson G; Hendrix SL; Cochrane BB; Kuller LH; Cauley JA
Arch Intern Med; 2009 Oct; 169(18):1684-91. PubMed ID: 19822825
[TBL] [Abstract][Full Text] [Related]
5. Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women's Health Initiative Randomized Clinical Trials.
Chlebowski RT; Anderson GL; Aragaki AK; Manson JE; Stefanick ML; Pan K; Barrington W; Kuller LH; Simon MS; Lane D; Johnson KC; Rohan TE; Gass MLS; Cauley JA; Paskett ED; Sattari M; Prentice RL
JAMA; 2020 Jul; 324(4):369-380. PubMed ID: 32721007
[TBL] [Abstract][Full Text] [Related]
6. Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials.
Manson JE; Aragaki AK; Rossouw JE; Anderson GL; Prentice RL; LaCroix AZ; Chlebowski RT; Howard BV; Thomson CA; Margolis KL; Lewis CE; Stefanick ML; Jackson RD; Johnson KC; Martin LW; Shumaker SA; Espeland MA; Wactawski-Wende J;
JAMA; 2017 Sep; 318(10):927-938. PubMed ID: 28898378
[TBL] [Abstract][Full Text] [Related]
7. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials.
Manson JE; Chlebowski RT; Stefanick ML; Aragaki AK; Rossouw JE; Prentice RL; Anderson G; Howard BV; Thomson CA; LaCroix AZ; Wactawski-Wende J; Jackson RD; Limacher M; Margolis KL; Wassertheil-Smoller S; Beresford SA; Cauley JA; Eaton CB; Gass M; Hsia J; Johnson KC; Kooperberg C; Kuller LH; Lewis CE; Liu S; Martin LW; Ockene JK; O'Sullivan MJ; Powell LH; Simon MS; Van Horn L; Vitolins MZ; Wallace RB
JAMA; 2013 Oct; 310(13):1353-68. PubMed ID: 24084921
[TBL] [Abstract][Full Text] [Related]
8. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators.
Greendale GA; Reboussin BA; Sie A; Singh HR; Olson LK; Gatewood O; Bassett LW; Wasilauskas C; Bush T; Barrett-Connor E
Ann Intern Med; 1999 Feb; 130(4 Pt 1):262-9. PubMed ID: 10068383
[TBL] [Abstract][Full Text] [Related]
9. Conjugated equine estrogen and medroxyprogesterone acetate are associated with decreased risk of breast cancer relative to bioidentical hormone therapy and controls.
Zeng Z; Jiang X; Li X; Wells A; Luo Y; Neapolitan R
PLoS One; 2018; 13(5):e0197064. PubMed ID: 29768475
[TBL] [Abstract][Full Text] [Related]
10. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin.
Heiss G; Wallace R; Anderson GL; Aragaki A; Beresford SA; Brzyski R; Chlebowski RT; Gass M; LaCroix A; Manson JE; Prentice RL; Rossouw J; Stefanick ML;
JAMA; 2008 Mar; 299(9):1036-45. PubMed ID: 18319414
[TBL] [Abstract][Full Text] [Related]
11. Effects of estrogen with and without progestin on urinary incontinence.
Hendrix SL; Cochrane BB; Nygaard IE; Handa VL; Barnabei VM; Iglesia C; Aragaki A; Naughton MJ; Wallace RB; McNeeley SG
JAMA; 2005 Feb; 293(8):935-48. PubMed ID: 15728164
[TBL] [Abstract][Full Text] [Related]
12. Breast Cancer After Use of Estrogen Plus Progestin and Estrogen Alone: Analyses of Data From 2 Women's Health Initiative Randomized Clinical Trials.
Chlebowski RT; Rohan TE; Manson JE; Aragaki AK; Kaunitz A; Stefanick ML; Simon MS; Johnson KC; Wactawski-Wende J; O'Sullivan MJ; Adams-Campbell LL; Nassir R; Lessin LS; Prentice RL
JAMA Oncol; 2015 Jun; 1(3):296-305. PubMed ID: 26181174
[TBL] [Abstract][Full Text] [Related]
13. Effects of oral conjugated equine estrogens with or without medroxyprogesterone acetate on incident hypertension in the Women's Health Initiative hormone therapy trials.
Swica Y; Warren MP; Manson JE; Aragaki AK; Bassuk SS; Shimbo D; Kaunitz A; Rossouw J; Stefanick ML; Womack CR
Menopause; 2018 Jul; 25(7):753-761. PubMed ID: 29381666
[TBL] [Abstract][Full Text] [Related]
14. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy.
Stefanick ML; Anderson GL; Margolis KL; Hendrix SL; Rodabough RJ; Paskett ED; Lane DS; Hubbell FA; Assaf AR; Sarto GE; Schenken RS; Yasmeen S; Lessin L; Chlebowski RT;
JAMA; 2006 Apr; 295(14):1647-57. PubMed ID: 16609086
[TBL] [Abstract][Full Text] [Related]
15. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial.
Chlebowski RT; Hendrix SL; Langer RD; Stefanick ML; Gass M; Lane D; Rodabough RJ; Gilligan MA; Cyr MG; Thomson CA; Khandekar J; Petrovitch H; McTiernan A;
JAMA; 2003 Jun; 289(24):3243-53. PubMed ID: 12824205
[TBL] [Abstract][Full Text] [Related]
16. Effect of estrogen therapy on gallbladder disease.
Cirillo DJ; Wallace RB; Rodabough RJ; Greenland P; LaCroix AZ; Limacher MC; Larson JC
JAMA; 2005 Jan; 293(3):330-9. PubMed ID: 15657326
[TBL] [Abstract][Full Text] [Related]
17. Sex hormone associations with breast cancer risk and the mediation of randomized trial postmenopausal hormone therapy effects.
Zhao S; Chlebowski RT; Anderson GL; Kuller LH; Manson JE; Gass M; Patterson R; Rohan TE; Lane DS; Beresford SA; Lavasani S; Rossouw JE; Prentice RL
Breast Cancer Res; 2014 Mar; 16(2):R30. PubMed ID: 24670297
[TBL] [Abstract][Full Text] [Related]
18. Estrogen-alone therapy and invasive breast cancer incidence by dose, formulation, and route of delivery: findings from the WHI observational study.
Shufelt C; Bairey Merz CN; Pettinger MB; Choi L; Chlebowski R; Crandall CJ; Liu S; Lane D; Prentice R; Manson JE;
Menopause; 2018 Sep; 25(9):985-991. PubMed ID: 29738414
[TBL] [Abstract][Full Text] [Related]
19. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study.
Espeland MA; Rapp SR; Shumaker SA; Brunner R; Manson JE; Sherwin BB; Hsia J; Margolis KL; Hogan PE; Wallace R; Dailey M; Freeman R; Hays J;
JAMA; 2004 Jun; 291(24):2959-68. PubMed ID: 15213207
[TBL] [Abstract][Full Text] [Related]
20. Postmenopausal hormone therapy and change in mammographic density.
Greendale GA; Reboussin BA; Slone S; Wasilauskas C; Pike MC; Ursin G
J Natl Cancer Inst; 2003 Jan; 95(1):30-7. PubMed ID: 12509398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
